What are the American Diabetes Association guidelines for screening, diagnosis, glycemic targets, lifestyle modification, pharmacologic therapy, blood pressure and lipid management, aspirin use, and monitoring in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 19, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

ADA Diabetic Guidelines for Adults

Screening Recommendations

All asymptomatic adults aged 35 years and older should be screened for diabetes in a healthcare setting using fasting plasma glucose (FPG), HbA1c, or 2-hour oral glucose tolerance test (OGTT). 1

Who to Screen

  • Universal screening starting at age 35 years for all adults, regardless of other risk factors 1, 2
  • Earlier screening (before age 35) if BMI ≥25 kg/m² (≥23 kg/m² for Asian Americans) AND any of the following risk factors: 1, 2, 3
    • First-degree relative with diabetes
    • High-risk ethnicity (African American, Latino, Native American, Asian American, Pacific Islander)
    • History of cardiovascular disease
    • Hypertension (≥140/90 mmHg or on therapy)
    • HDL cholesterol <35 mg/dL and/or triglycerides >250 mg/dL
    • Physical inactivity
    • Women with prior gestational diabetes or who delivered a baby >9 lb
    • Polycystic ovary syndrome (PCOS)
    • Previous impaired fasting glucose (IFG) or impaired glucose tolerance (IGT)

Screening Frequency

  • Every 3 years if initial screening is normal (FPG <100 mg/dL, 2-hour plasma glucose <140 mg/dL, HbA1c <5.7%) 1, 2, 3
  • Annually for patients with prediabetes (FPG 100-125 mg/dL, HbA1c 5.7-6.4%, or 2-hour OGTT 140-199 mg/dL) 1, 3
  • More frequently for high-risk individuals with multiple risk factors or weight gain 3

Diagnostic Criteria

Diabetes is diagnosed when any of the following criteria are met (must be confirmed on a separate day unless patient has unequivocal hyperglycemic symptoms): 1, 3

  1. HbA1c ≥6.5% (48 mmol/mol) using NGSP-certified laboratory method 1
  2. Fasting plasma glucose ≥126 mg/dL (7.0 mmol/L) after 8-hour fast 1, 2, 3
  3. 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during 75-g OGTT 1, 3
  4. Random plasma glucose ≥200 mg/dL (11.1 mmol/L) with classic symptoms (polyuria, polydipsia, unexplained weight loss) 1

Prediabetes Categories

  • Impaired fasting glucose (IFG): FPG 100-125 mg/dL (5.6-6.9 mmol/L) 1, 2
  • Impaired glucose tolerance (IGT): 2-hour OGTT 140-199 mg/dL (7.8-11.0 mmol/L) 1, 2
  • Elevated HbA1c: 5.7-6.4% (39-47 mmol/mol) 1, 2

Preferred Screening Test

Fasting plasma glucose (FPG) is the preferred screening test because it is practical, reproducible, cost-effective, more convenient for patients, and has less intraindividual variation than alternatives. 2, 4

  • HbA1c is a convenient alternative requiring no fasting 1, 4
  • OGTT is more cumbersome, time-consuming, expensive, and has highest intraindividual variability 4
  • Point-of-care HbA1c assays should NOT be used for diagnosis 1

Glycemic Targets

Target HbA1c <7.0% in most adults with diabetes to reduce microvascular complications. 3

  • Recheck HbA1c after 3 months of treatment initiation or adjustment 3
  • If HbA1c target not reached after 3 months, add a second agent 3

Lifestyle Modification

Lifestyle intervention is first-line therapy for prediabetes and an essential adjunct to pharmacotherapy in diabetes. 3

Physical Activity

  • ≥150 minutes per week of moderate-intensity aerobic activity (approximately 700 kcal/week energy expenditure), spread over at least 3 days with no more than 2 consecutive days without activity 3
  • Resistance training at least twice per week 3
  • Break up prolonged sedentary periods to lower postprandial glucose excursions 3

Dietary Recommendations

  • Mediterranean or DASH dietary pattern emphasizing whole grains, legumes, nuts, fruits, vegetables, and minimal processed foods 3
  • Eliminate sugar-sweetened beverages entirely 3
  • Sodium intake <2,300 mg/day 3
  • Reduce saturated fat, trans fat, and cholesterol; increase omega-3 fatty acids, viscous fiber, and plant sterols/stanols 3

Pharmacologic Therapy

Initial Therapy for Type 2 Diabetes

Initiate metformin at diagnosis of type 2 diabetes unless contraindicated. 3

  • Verify adequate renal function before starting: serum creatinine <1.5 mg/dL in men, <1.4 mg/dL in women 3
  • Measure serum creatinine at least annually and whenever metformin dose is increased 3

Treatment Escalation Algorithm

  • If HbA1c ≥9.0% at diagnosis: Add basal insulin for robust glucose lowering 3
  • If HbA1c remains ≥7.0% after 3 months on metformin: Add a second agent 3
  • Consider GLP-1 receptor agonist for additional weight loss and cardiovascular protection 3
  • Avoid sulfonylureas in older adults due to prolonged half-life and heightened hypoglycemia risk 3

Prediabetes Pharmacotherapy

Consider metformin for high-risk individuals with prediabetes: BMI ≥35 kg/m² or age <60 years with prediabetes. 3

  • Metformin has the strongest evidence base and long-term safety for diabetes prevention 3

Blood Pressure Management

Target blood pressure <130/80 mmHg in adults with diabetes. 3

  • Measure blood pressure at every routine diabetes visit 3
  • For BP 130-139/80-89 mmHg: Initiate lifestyle therapy (weight loss, DASH diet, sodium reduction, potassium increase, alcohol moderation, physical activity) for up to 3 months; add pharmacologic agents if targets remain unmet 3
  • For BP ≥140/90 mmHg: Start pharmacologic therapy immediately in addition to lifestyle measures 3

Lipid Management

Obtain fasting lipid profile at least annually (or every 2 years if low-risk: LDL <100 mg/dL, HDL >50 mg/dL, triglycerides <150 mg/dL). 3

Statin Therapy Indications

Add statin therapy to lifestyle treatment for: 3

  • All diabetic patients with overt cardiovascular disease
  • All diabetic patients >40 years with one or more cardiovascular risk factors, even without established disease

LDL-Cholesterol Targets

  • Primary goal: LDL <100 mg/dL in individuals without overt cardiovascular disease 3
  • Optional intensive goal: LDL <70 mg/dL using high-dose statin in patients with established cardiovascular disease 3
  • If LDL targets not achieved on maximal tolerated statin: Aim for 30-40% reduction from baseline 3

Aspirin Use

The 2023 ADA guidelines do not provide specific aspirin recommendations in the evidence provided. However, based on general cardiovascular risk management principles in diabetes, aspirin use should be individualized based on cardiovascular risk assessment and bleeding risk. 3

Monitoring

Glycemic Monitoring

  • HbA1c every 3 months until glycemic target achieved, then at least twice yearly if stable 3
  • Self-monitoring of blood glucose as appropriate for medication regimen

Cardiovascular Risk Factor Monitoring

  • Blood pressure at every routine visit 3
  • Fasting lipid profile annually (or every 2 years if low-risk) 3
  • Serum creatinine at least annually and when adjusting metformin dose 3

Immunizations

  • Annual influenza vaccine for all diabetic patients aged ≥6 months 3
  • Pneumococcal polysaccharide vaccine for all diabetic patients aged ≥2 years; one-time revaccination for those <64 years who were previously immunized before age 65 and >5 years have elapsed 3
  • Hepatitis B vaccination per CDC recommendations 3

Special Populations

Pediatric Screening

Perform risk-based screening after puberty onset or after age 10 years (whichever is earlier) in children/adolescents with overweight or obesity PLUS at least one additional risk factor (maternal diabetes, family history of type 2 diabetes, high-risk ethnicity, signs of insulin resistance). 3

End-of-Life Care

  • Stable patients: Continue existing regimen emphasizing hypoglycemia prevention; maintain glucose below renal threshold 3
  • Patients with organ failure: Prioritize hypoglycemia avoidance; for type 1 diabetes, reduce but do not stop insulin; for type 2 diabetes, titrate agents that carry hypoglycemia risk 3
  • Dying patients: Discontinue all diabetes medications for type 2 diabetes; for type 1 diabetes, maintain small basal insulin dose to avert acute hyperglycemic complications 3

Critical Pitfalls to Avoid

  • Do NOT wait until age 45 for overweight/obese patients with risk factors—screen immediately 2
  • Always confirm abnormal results with repeat testing on a separate day unless patient has unequivocal hyperglycemic symptoms 1, 2, 3
  • Do NOT rely on random blood glucose alone for screening—sensitivity is only 39-55% 2
  • Do NOT use HbA1c alone in patients with hemoglobinopathies or conditions affecting red-cell turnover—confirm diagnosis with plasma glucose testing 3
  • Do NOT conduct community-based screening outside healthcare settings—ensures proper follow-up and appropriate targeting of high-risk populations 2, 3
  • Do NOT use point-of-care HbA1c assays for diagnosis—only NGSP-certified laboratory methods are acceptable 1

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

2
Guideline

Screening and Diagnosis of Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3
Guideline

Diabetes Mellitus Screening and Management Guidelines for Adults

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

4
Guideline

Best Screening Test for Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

At what age should patients be screened for Diabetes Mellitus (DM)?
At what age should Diabetes Mellitus (DM) screening commence?
When should diabetes screening be initiated in adults, what risk factors warrant earlier screening, and which diagnostic tests are appropriate?
What are the guidelines for diabetes screening and management?
At what age should ADA screening for Diabetes Mellitus (DM) begin in asymptomatic adults with no risk factors?
How should I give a digoxin loading dose and continuous intravenous infusion in an adult (e.g., 70‑kg) patient, including dosing, monitoring, and transition to oral therapy?
In a patient with diabetic ketoacidosis receiving a continuous insulin infusion who becomes hypoglycemic, how should the hypoglycemia be managed?
What is the recommended emergency and subsequent management for a patient presenting with an acute myocardial infarction?
How many days before an elective surgery should clopidogrel be discontinued, and what is the recommended management for patients with high thrombotic risk (e.g., recent coronary stent placement or acute coronary syndrome)?
What are the current Indian National AIDS Control Organisation recommendations for first‑line and second‑line antiretroviral therapy in treatment‑naïve HIV‑positive adults, including the preferred regimen, alternatives for renal impairment, monitoring schedule, treatment‑failure criteria, and special considerations for tuberculosis co‑infection and pregnancy?
Why is pyridoxine (vitamin B6) given with an isoniazid‑containing anti‑tuberculosis regimen?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question